We advised PegBio on the placement of new shares

Davis Polk advised PegBio Co., Ltd. on its placement of 5,136,000 new H shares, for an aggregate consideration of approximately HK$300 million.

Davis Polk also advised PegBio on its IPO in May 2025. The shares are listed on the Hong Kong Stock Exchange.

PegBio is a biotechnology company focused on the in-house discovery and development of innovative therapies – primarily peptide and small molecule drugs – for chronic diseases, with a particular emphasis on metabolic disorders.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel – registered foreign lawyer Jennifer (Yujia) Jiang, counsel Wendy Kan and associate Marco Cheng. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post